

Predictors of persistent Medically Unexplained physical Symptoms: findings from a general population study

Jonna F van Eck van der Sluijs,^{1,2} Margreet ten Have,³ Ron de Graaf,³ Cees A Th Rijnders,⁴ Harm WJ van Marwijk,⁵ Christina M van der Feltz–Cornelis^{1,2}

1 Clinical Centre of Excellence for Body, Mind and Health, GGz Breburg

2 Tranzo Department, Tilburg University, Tilburg

3 Netherlands Institute of Mental Health and Addiction, Utrecht

4 Department of Residency training, GGz Breburg, Tilburg, the Netherlands

5 Division of Primary Care and Public Health, Brighton and Sussex Medical School, University of Brighton, United Kingdom

Abstract

Objective: The aim of this study was to explore the course of Medically Unexplained Symptoms (MUS) and its prognostic factors in the general adult population. Knowledge of prognostic factors of MUS may indicate possible avenues for intervention development.

Methods: Data were derived from the Netherlands Mental Health Survey and Incidence Study–2 (NEMESIS–2), a nationally representative face-to-face cohort study among the Dutch general population aged 18–64 years. We selected subjects with MUS at baseline and who participated at follow-up (N=324) and reassessed those subjects for having MUS at three year follow-up. Logistic regression analyses were used to determine risk factors for persistency of MUS.

Results: 36.4% of the subjects had persistent MUS at follow-up. In logistic regression analyses adjusted for sex and age, persistency of MUS was predicted by the presence of comorbid chronic medical disorder(s), lower education, female sex, not having a paid job, parental psychopathology as well as lower functioning. In the logistic regression analysis in which all significant variables adjusted for sex and age were entered simultaneously, only two variables predicted persistent MUS: the presence of comorbid chronic medical disorder(s) and parental psychopathology, with odds ratios of 1.98 (95%CI 1.18–3.32) and 1.84 (95%CI 1.10–3.08), respectively.

Conclusion: In the adult general population, MUS were persistent in over one third of the subjects with MUS at baseline. Persistency was uniquely predicted by parental psychopathology and having comorbid chronic medical disorders. These findings warrant further research into early intervention and treatment options for persons with an increased risk of persistent MUS.

Keywords: Medically Unexplained Symptoms, Course, Prognosis, Persistency, General population

Introduction

Background

Persons with Medically Unexplained physical Symptoms (MUS) are highly prevalent in health care settings (1), and in the general population (2, 3). MUS can be defined as physical symptoms for which a physician cannot find a sufficient explanation after proper medical examination (4–6). Persistent MUS can be severe and disabling (7–11), and lead to high health care use (12) and high costs (13). Persons with persistent MUS can be tempted to seek treatments that are not supported by scientific evidence, such as prolonged and unorthodox antibiotic regimes in case of Lyme disease even when there is no evidence of the infection (14). We know little about the prognosis of persons with MUS in the general population and its determinants, as previous longitudinal research was mainly performed in selected groups, namely hospital or primary care patients. More precise estimates of how many persons with MUS –i.e. in the general population– suffer persistently from MUS, and what factors influence their course facilitate resource and care planning and may indicate possible avenues for future intervention development. This is needed, because such interventions, can perhaps lead to a more favorable course of MUS and thereby reduce the heavy burden and impairment persons with persistent MUS can experience and they can help to possibly reduce costs.

Among patients with MUS in a general medical outpatient clinic, respectively 29 and 24% of the patients still had MUS at 11.6 and 15.2 months follow-up (15, 16). In another study in a general medical outpatient clinic with a mean follow-up of 61 weeks, 38% of the patients reported that their symptoms persisted (17). Among patients with MUS in a neurology outpatient clinic with 8 months follow-up, as much as 54% of the MUS persisted (18). Persistence of MUS was predicted by a longer duration of the MUS at baseline (17), higher number of (either explained or unexplained) physical symptoms at baseline (16, 17), and female gender (16).

In primary care, 51.2% of the MUS at baseline persisted during the course of one year (1). In over half of these patients the main MUS was pain. Significant predictors for persistent MUS after one year among these primary care patients with MUS were: negative life events, autonomic sensations (the experience of bodily symptoms), and the attribution of MUS to somatic disease –rather than psychological factors– by the patient (1). Another study found negative affect –which is closely associated with depression– to be an important determinant of persistent MUS, most probably because

it contributes to symptom evolution as well as symptom severity, whereas positive affect has a beneficial effect on somatic symptom evolution (19). A systematic review concludes that because of a lack of rigorous empirical evidence, more research is needed to identify relevant prognostic factors for the course of MUS (10), as these are needed to develop effective interventions.

In the general population, even less is known about the course of MUS in adults; and research mainly focused on adolescents. Possibly, higher percentages of persistency can be found in selected secondary or primary care patient groups with MUS compared to in the general population, because those would be the more severe and chronic cases of MUS (a phenomenon sometimes described as the 'iceberg'). Persistent MUS was found in only 4.1% of community adolescents with MUS at baseline (mean age 11.1 years) over a period of five years (mean age at reassessment 16.3 years) (20). In these adolescents, risk factors measured at baseline of the study for persistent MUS were female gender, presence of depressive symptoms, poor self-rated health, and parents' report of a high number of MUS among their adolescent child (20). In another study it was found that subjects who score high (above the 90th percentile of the total score) on various symptoms, MUS tend to persist more often from childhood to adulthood when compared to low-scoring subjects (21). Perfectionism was also found to be associated with the persistence of MUS, this effect was significantly mediated by symptoms of anxiety and depression (22). Childhood adversities such as abuse and neglect increased the risk of diverse chronic physical conditions in later life (23); possibly this is also the case for MUS.

To our knowledge, only the course and predictors of medically unexplained *pain* symptoms (MUS–pain) have been studied in the adult general population (24). One third (33.6%) of MUS–pain was persistent, when measured over an 11 years interval. From the possible predictors measured at baseline, only female gender was a risk factor for persistence of MUS–pain. These results on MUS–pain cannot be generalised to all MUS, because MUS such as dizziness, overtiredness, nausea and irritable bowel syndrome could have different risk factors for persistence compared to pain. If those risk factors can be influenced or treated, this is important information for the development of interventions. From a clinical perspective, a shorter follow-up course of a few years may be more relevant than a much longer period of time, and will possibly result in more risk-indicators than were found in the study of Leiknes and colleagues who only focused on MUS–pain over a period of 11 years (24).

The aim of this study is to estimate the course of MUS and explore prognostic factors among the adult general population. Prognostic factors can be categorized as demographic variables, vulnerability (e.g. trauma, negative life events), comorbid mental and physical disorders, and mental and physical

functioning. This study will add to the body of literature, given that the previous literature mainly focused on selected groups, i.e. patients seen by doctors (in primary care (1, 10, 19) or clinical setting (15–18)). These selected patient groups comprise especially those persons with MUS with a high burden of MUS (25), and high costs (13). Insight in the course of MUS and its predicting factors in the general population is important, because it will tell us which MUS have a high risk of becoming persistent.

Objective

Our objective is to estimate the course of MUS (i.e., persistency) and to determine what factors influence its course in the adult general population. Based on previous findings, we hypothesize that female gender, childhood trauma, presence of negative life events, presence of common mental disorders, presence of comorbid chronic medical disorder(s), and worse physical or general functioning –all measured at baseline– are associated with persistence of MUS measured at 3-year follow-up.

Methods

Study design

In this general population study, we examine what the course of MUS is and what factors are associated with persistence of MUS, over three years. We report our findings according to the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) statement (26).

Setting and participants

Data were derived from the Netherlands Mental Health Survey and Incidence Study–2 (NEMESIS–2). Methods of NEMESIS–2 are described in details elsewhere (27, 28). Here, we give a short description, which has been published earlier (29). NEMESIS–2 was approved by a medical ethic Committee (METIGG). After being informed about the study, subjects provided written informed consent. For this paper, data were used from the first wave (T_0), performed from November 2007 to July 2009, and the second wave (T_1), performed from November 2010 to June 2012.

NEMESIS–2 is based on a multistage, stratified random sampling of households, with one respondent aged 18–64 years randomly selected in each household for a face-to-face interview. The interviews were conducted by professional, experienced interviewers. The response rate was 65.1%. The sample was nationally representative, although younger subjects were somewhat underrepresented. Of the

6646 baseline subjects, 140 subjects received a shortened version of the questionnaire, and as a consequence they did not receive questions about somatic disorders. Therefore, the number of subjects available at T_0 was 6506 of which 386 subjects had MUS at T_0 . Of those 386, data were available of 324 subjects at T_1 . Those 324 subjects comprised our study cohort. They were assessed at T_0 for the possible predicting factors for persistency of MUS, and reassessed for having MUS at T_1 . The attrition rate at three year follow-up for the 6,646 baseline subjects was 20.2%. The presence of psychopathology in the past 12 months at baseline was not significantly associated with attrition, after controlling for sociodemographic characteristics (30). The attrition rate for the 386 subjects with MUS at T_0 was 16.1%; none of the variables presented in table 2 that were measured at T_0 were statistically significant associated with this attrition. Also having MUS at T_0 was not statistically significantly associated with attrition at T_1 .

Variables

We use the following definition of MUS (29): presence of one or more physical symptom(s) in the past 12 months for which no adequate organ pathology or pathophysiological basis was found, and for which, according to the subject, a physician was consulted and/or medication was received, and which caused discomfort and functional impairment in the past 4 weeks as measured by the Short Form 36 (SF-36) (31). In line with the Somatic Symptom Disorder (SSD) definition in the *Diagnostic and Statistical Manual of Mental Disorders*, fifth edition (DSM-5) (32), we included the presence of discomfort and functional impairment in our definition. Persistence of MUS is defined as presence of MUS at both T_0 and T_1 .

Data sources/measurement

The measuring instruments for MUS and the possible predictors of persistent MUS are described in table 1 (partially published in our previous studies (29, 33)).

Bias

All definitions in table 1 were predefined, and as strict as possible defined to support unambiguous interpretation. Definitions are in line with previously published papers using data from NEMESIS-2 (29, 33). Given that the data had already been collected by independent researchers, results could not be influenced by the authors. There were no missing data for most of the possible predictors of persistence at baseline. Only household income had 21 missings (6.5%) and the role-emotional scale of the SF-36 had one missing (0.3%).

Quantitative variables and study size

324 subjects of the 386 subjects with MUS at T₀ could be reassessment at T₁. Those 324 were reassessed for having MUS at 3-year follow-up, and were assessed for the possible prediction factors for the persistency of MUS as described in table 1.

Statistical methods

All analyses were performed using STATA version 12.1. Given the relatively small group of subjects with MUS (i.e. 324 respondents), unweighted data were used. In order to describe the percentage that persisted in having MUS at follow-up, we performed a cross-tabulation of MUS-cases at T₁. In order to define what risk factors at baseline influence persistency of MUS at follow-up (yes/no), we performed logistic regression analyses adjusted for sex and age (table 2: model 1). In the next step, all significant variables adjusted for sex and age from model 1 were entered simultaneously in one more fully adjusted logistic regression analysis (table 2: model 2), to find unconfounded estimates of risk factors for persistency. To test for linear trends, potential determinants (i.e. age, education level, and household income) were also modelled separately as continuous variables (P for trend test).

Results

Outcome data and main results

Of the 324 subjects with MUS at baseline, 118 (36.4%) had persistent MUS, meaning they had MUS at both T₀ and T₁. Table 2 (model 1) shows that, in subjects with MUS at baseline, having persistent MUS is statistically significant predicted by female sex (OR 1.79; 95%CI 1.08–2.97), not having a paid job (OR 1.65; 95%CI 1.01–2.69), lower education (OR 1.89; 95%CI 1.03–3.48), parental psychopathology (1.71; 95%CI 1.05–2.78) and having comorbid chronic medical disorder(s) (OR 1.96; 95%CI 1.19–3.21). A lower odds of having persistent MUS, is statistically significantly predicted by a higher score (meaning better functioning) on four scales of the SF-36. Those scales comprised social functioning (OR 0.99; 95%CI 0.98–10.00), bodily pain (0.98; 95%CI 0.97–0.99), physical functioning (0.98; 95%CI 0.97–0.99) and general health (0.98, 95%CI 0.97–0.99). The SF-36 subscales range from 0 to 100, the ORs refer to a 1-point increase of the subscales. The other variables shown in table 2 did not statistically significantly predict persistency of MUS. Besides any 12-month mental disorder, persistency of MUS was also not statistically significant predicted by any 12-month mood disorder (OR

1.13; 95%CI 0.36–2.28) and any 12-month anxiety disorder (OR 1.30; 95%CI 0.73–2.31) (not shown in table).

For the variables that were subdivided in three or more categories (age, education level and household income) a p for trend was calculated. No statistically significant association was found with increasing age, education level and household income and odds of having persistent MUS (see table 2).

Multivariate analyses

A multivariate analysis was performed with the statistically significant findings ($p < 0.05$) from the analyses adjusted for sex and gender. Of those, only parental psychopathology (OR 1.98; 95%CI 1.18–3.32) and comorbid chronic medical disorder(s) (OR 1.84; 95%CI 1.10–3.08) remained statistically significant predictors for having persistent MUS after three years. Female sex, not having a paid job, education level and social functioning, bodily pain, physical functioning and general health did not statistically significantly predict persistency of MUS anymore (table 2; model 2).

Discussion

Key results and interpretation

To our knowledge, this is the first study that explores the course of MUS in the adult general population. The findings are that over a three-year follow-up, 36.4% of our sample with MUS at baseline had persistent MUS. Persistency of MUS is predicted by having comorbid chronic medical disorder(s), lower education, female sex, parental psychopathology, and not having a paid job; in the bivariate logistic regression analysis. A lower odds of having persistent MUS is predicted by better functioning as measured with the SF-36 in the areas social functioning, bodily pain, physical functioning and general health. Our hypothesis about which variables predict persistency of MUS is confirmed –in the logistic regression analyses adjusted for sex and age (table 2: model 1) – for having comorbid chronic medical disorder(s), female gender, and partly for mental and physical functioning. These findings are in line with previous studies (15–18, 20). An association between worse physical functioning at baseline measured with the SF-36 and persistent MUS at follow-up was found before in neurology patients (18). A possible explanation for the other variables that predicted persistency of MUS –namely lower education, parental psychopathology, and not having a paid job– is that they can have a negative influence on overall functioning and well-being (34–37). Also resilience can be negatively impacted by life stressors such as unemployment (38).

Parental psychopathology had the highest OR in the multivariate logistic regression model, followed by having comorbid chronic medical disorder(s). The other predictors found in the logistic regression analyses adjusted for sex and gender (model 1) were not statistically significant in the more fully adjusted logistic regression analysis (model 2). Having comorbid chronic medical disorder(s) as a predictor for persistence of MUS is in line with previous research (16, 17). A possible explanation is, that it is more difficult to adequately cope with physical symptoms when they are partly MUS and partly due to a chronic medical disorder. Besides the abovementioned overall negative effects of parental psychopathology and of functioning or well-being, an association was found between both paternal and maternal depression and increased risk of psychopathology in their offspring (39–41). Apparently, parental psychopathology is an indicator for vulnerability, which is also expressed in the increased risk of persistent MUS.

In the less and more fully adjusted logistic regression analyses (model 1 and model 2), no statistically significant ORs were found for partner status, age, household income, any childhood trauma before age 16, any 12 months negative life event, any 12 month common mental disorder, and lower levels of functioning measured with the SF-36 in the subscales emotional role functioning, mental health, vitality and physical role functioning at baseline. This means our hypothesis about what variables predict persistency of MUS is not confirmed for childhood trauma, presence of negative life events, and presence of common mental disorders. Childhood adversities increase the risk of diverse chronic physical conditions –such as hypertension, heart disease and asthma– later in life (23, 42). Childhood adversities are also associated with the onset of mental disorders later in life (43)], and childhood sexual abuse was found to be associated with MUS as well as chronic pelvic pain in previous research (44, 45). We therefore were surprised that we did not find similar results with regard to the persistency of MUS. Possibly, the fact that the current research is performed in the general population instead of in a selected patient group is of influence on this. Further research exploring the association between childhood adverse events and (explained or unexplained) physical symptoms is therefore warranted. MUS are associated with higher odds of having common mental disorders (29), but in this study we did not find a higher odds of having persistent MUS when common mental disorders were present at baseline

Research performed in general hospital and in primary care showed persistency rates of 24 to 54% (1, 15–18), with follow-up times varying from 8 to 15 months. In the general population, persistence MUS was found in 33.6% of MUS-pain, with an 11 year follow-up (24). The percentage of persistency we found in this study, 36.4%, does not differ largely from the persistency rates found in the majority of

the beforementioned studies. However, the follow-up period varies between the studies, which makes it difficult to compare these persistency rates. We expected higher persistency rates when follow up periods are shorter, but when we compare these studies, there is no clear relation between length of follow-up and persistency rate.

Limitations

In our study, persistency of MUS is based on how patient rate their unexplained physical symptoms, which is also the case in several other studies (15, 16, 18, 24). There are also studies where the physical symptoms are rated by a physician, namely a general practitioner (1) or an internist (17). We included the presence of discomfort and functional impairment in our definition of MUS, in order to approach the criteria of the Somatic Symptom Disorder as described in the DSM 5 (32). Although we used an existing database, we believe our methods of operationalization and classification are reasonable for MUS. However, a limitation is that we do not know the onset date of the MUS, we only know whether or not the MUS were present at To, but not for how long already.

Generalizability

NEMESIS-2 is a large, nationally representative sample of the adult Dutch general population. Therefore, the results of this study can be extrapolated to the general population of the Netherlands, and possibly to more countries.

Conclusion

In this general population study, MUS are persistent in 36.4% measured over a three-year interval. Persistency is uniquely predicted by parental psychopathology and having comorbid chronic medical disorder(s). The parental psychopathology is an interesting subject for further research, given that it can possibly lead to early interventions and specific treatment options. For example, when the stepped care approach as described in the Dutch guideline for treatment of MUS (6) is used, collaboration with or referral to a physiotherapist or psychologist could be recommended in an early stage for persons with a high risk of having persistent MUS.

Funding

NEMESIS-2 is conducted by the Netherlands Institute of Mental Health and Addiction (Trimbos Institute) in Utrecht. Financial support has been received from the Ministry of Health, Welfare and Sport, with

Predictors of persistent MUS (21–02–2018)

supplementary support from the Netherlands Organization for Health Research and Development (ZonMw) and the Genetic Risk and Outcome of Psychosis (GROUP) investigators.

Table 1: Variables: definitions and measurement instruments

Measurement	Measuring instrument
Medically unexplained physical symptoms	
<p>Subjects were considered to have MUS if their condition applied to both criteria mentioned below:</p> <p>1. Presence of one of the following physical symptoms, experienced in the past 12 months, for which the subjects indicated that they visited a physician and/or received medication:</p> <p>a) Disturbing intestinal symptoms, existing longer than 3 months, for which no indication of an explanation existed.(46–48)</p> <p>b) Back problems existing longer than 3 months, for which no indication of an explanation existed.(47, 49)</p> <p>c) Other illness or physical symptoms that are long lasting (open question) and unexplained</p> <p>2. Presence of limited functioning reported in the past 4 weeks, as indicated by two or more of the physical health subscales of the SF–36.(31, 50)</p>	<p>Interview based on a questionnaire of physical symptoms.</p> <p>All physical symptoms mentioned here (verbatim responses) were checked independently by two physicians (JES and CFC) to indicate whether or not they could be considered medically unexplained physical symptoms in general. If their judgments were not the same, they deliberated until consensus was achieved.</p> <p>We checked the answers on the open questions to see if an explanation was given about the intestinal symptoms, such as pancreatitis or hernia abdominalis, or the back problem, such as neck hernia or paraplegia. If this was the case, we did not include the subject in the unexplained group, but in the explained group.</p> <p>Examples of general symptoms that we considered to be medically unexplained physical symptoms are fibromyalgia, fatigue (such as chronic fatigue syndrome), pain without medical explanation (such as stress related pain in muscles), and physical symptoms accompanied with phrases such as ‘they can’t find anything’ or ‘if only I knew’.</p> <p>Interview based on the SF–36 physical health subscales:</p> <p>a) Physical functioning: some or severe limitations in at least one of the ten items in this category</p> <p>b) Physical role functioning: any limitation reported in at least one of the four items in this category</p> <p>c) Bodily pain: pain leading to any limitation in normal work activities</p>

	d) General health: describes mental or physical health as poor, and/or negative expectations about one's health.
Possible predicting factors of persistence of MUS	Face-to-face interview
<u>Sex</u>	Male/female
<u>Partner status</u>	Living with or without partner
<u>Age</u>	Based on the date of birth, divided in four age groups: a) 18-34 year b) 35-44 year c) 45-54 year d) 55-64 year Note: age groups 18-24 years and 25-34 years were put together because of the small number of respondents per group; respectively n=7 and n=34.
<u>Employment situation</u>	Describes whether the subject has a paid job. Not only the main work situation was taken into account, but also any other type of work situations (e.g. a student who also has a paid employment, will be counted as having a paid job).
<u>Education</u>	Self-report: a) Primary, basic vocational or lower secondary b) Higher secondary c) Higher professional, University
<u>Household income</u>	Self-report: classification in based on the average income in the Netherlands in 2007 (€1500 net income per month) a) Low: less than average; ≤1500 euro net per month b) Middle: 1 to 2 times average; 1501-3300 euro net per month c) High: more than 2 times average; >3300 euro net per month

<p><u>Childhood trauma before age 16</u></p>	<p>Self-report of emotional neglect (not listened to, ignored or unsupported), psychological abuse (yelled at, insulted, unjustly punished/treated, threatened, belittled or blackmailed), physical abuse ((kicked, hit, bitten or hurt with object or hot water) or sexual abuse (any unwanted sexual experience) before age 16. Emotional, psychological or physical abuse was scored present if the respondent reported this had occurred more than once. Sexual abuse was also scored present if the respondent reported this had occurred once.</p>
<p><u>Parental psychopathology:</u></p>	<p>Lifetime mental problems parents. These questions were asked at T1 .</p>
<p><u>Negative life events</u></p>	<p>The presence of 10 negative life events in the past 12 months, based on the 'Brugha Life events section' (51)</p>
<p><u>Comorbid chronic medical disorder(s):</u> Respiratory disorders (asthma, chronic obstructive pulmonary disease, chronic bronchitis, emphysema), cardiovascular disorders (severe heart disease, heart attack, hypertension, stroke), stomach or intestinal ulcers, severe intestinal symptoms (only if an explanation about the cause was given such as pancreatitis, hernia abdominalis), diabetes, thyroid disorder, chronic back pain (only if an explanation about the cause was given such as neck hernia, paraplegia, caused by accident), arthritis, migraine, cancer, impaired vision or hearing.</p>	<p>Interview based on questionnaire of physical symptoms, in which the main physical symptoms of the CBS (Statistics Netherlands) questionnaire can be found.(52) These physical symptoms were based on self-report by the subjects during the interview, and not by medical records.(53) Comparisons between self-reports of chronic physical disorders and medical records show moderate to good concordance.(54–56) Subjects were considered to have comorbid chronic medical disorder(s) if they reported to have been treated or monitored by a physician in the prior 12 months for one or more of the disorders, and after confirmation by two physicians (JES and CFC), in duplicate, that symptoms should be considered to be medically explained.</p>
<p><u>DSM-IV mental disorders:</u> DSM-IV mood disorder (major depression, dysthymia, bipolar disorder), anxiety disorder (panic disorder, agoraphobia (without panic disorder), social phobia, specific phobia, generalized anxiety disorder) and substance use disorder (alcohol/drug abuse and dependence). Here we combined the 12-month mood, anxiety and substance use disorders, to form the group 'any 12-month mental disorder'.</p>	<p><u>Composite International Diagnostic Interview Version 3.0 (CIDI 3.0)(53, 57, 58):</u> The interviews were conducted by professional, experienced interviewers. Clinical calibration studies conducted in various countries have found that CIDI 3.0(59) and earlier versions (60, 61) assess anxiety, mood and substance use disorders with generally good validity compared to blinded clinical reappraisal interviews.</p>

<u>Functioning</u>	<u>Score (0–100) –low to high functioning– on the SF–36 sections:</u>
a) Social role functioning	a) Social functioning scale
b) Emotional role functioning	b) Role–emotional scale
c) Mental health	c) Mental health scale
d) Vitality	d) Vitality scale
e) Bodily pain	e) Bodily pain
f) Physical functioning	f) Physical functioning
g) Physical role functioning	g) Role–physical scale
h) General health perceptions	h) General health

Table 2 Predictors of persistence of MUS (N= 324)

Odds ratio (OR) with 95% Confidence Interval (CI) or mean with standard error (se), adjusted for sex and age (model 1), or adjusted for all variables in this column (model 2).

	%	OR (95%CI) Model 1	OR (95%CI) Model 2
Demographic variables			
<i>Sex</i>			
Female	66.7	1.79 (1.08–2.97)*	1.24 (0.72,2.13)
<i>Partner status</i>			
No partner	34.3	0.75 (0.46–1.23)	
<i>Age</i>			
18–34	13.3	1	
35–44	21.6	1.26 (0.54–2.93)	
45–54	30.2	2.04 (0.93–4.48)	
55–64	34.9	1.81 (0.83–3.94)	
p for trend		0.084	
<i>Employment situation</i>			
No paid job	42.3	1.65 (1.01–2.69)*	1.11 (0.65,1.88)
<i>Education</i>			
Primary, basic vocational or lower secondary	42.0	1.89 (1.03–3.48)*	1.76 (0.91,3.41)
Higher secondary	31.8	1.80 (0.95–3.41)	1.87 (0.95,3.67)
Higher professional or university	26.2	1	1
p for trend		0.053	
<i>Household income</i>			
Low	32.4	1	
Middle	50.8	0.70 (0.41–1.19)	
High	16.8	0.55 (0.26–1.16)	
p for trend		0.088	
Vulnerability			
Any childhood trauma before age 16	41.1	1.24 (0.77–1.99)	

Predictors of persistent MUS (21-02-2018)

Parental psychopathology: lifetime mental problems parents at T1	38.3	1.71 (1.05–2.78)*	1.98 (1.18,3.32)*
Any negative life event in the 12 months before baseline	66.1	0.74 (0.45–1.19)	
Comorbid mental and physical disorders			
Comorbid chronic medical disorder(s)	55.3	1.96 (1.19–3.21)*	1.84 (1.10,3.08)*
Any 12-month common mental disorder at baseline	28.7	1.47 (0.89–2.43)	
Mental and physical functioning (scale 0–100)	mean (se)		
Social role functioning	76.0 (1.44)	0.99 (0.98–1.00)*	1.00 (0.99,1.01)
Emotional role functioning	85.3 (1.80)	1.00 (0.99–1.01)	
Mental health	78.7 (0.90)	1.00 (0.98–1.01)	
Vitality	58.0 (1.11)	0.99 (0.98–1.00)	
Bodily pain	54.1 (1.29)	0.98 (0.97–0.99)*	0.99 (0.98,1.00)
Physical functioning	66.9 (1.27)	0.98 (0.97–0.99)*	0.99 (0.97,1.00)
Physical role functioning	44.3 (2.33)	0.99 (0.99–1.00)	
General health perceptions	50.1 (1.09)	0.98 (0.97–0.99)*	0.99 (0.98,1.01)

Model 1: adjusted for sex and age.

Model 2: adjusted for all variables in this column.

* p < 0.05

References

1. Steinbrecher N, Hiller W. Course and prediction of somatoform disorder and medically unexplained symptoms in primary care. *Gen Hosp Psychiatry*. 2011;33(4):318–26.
2. Janssens KA, Zijlema WL, Joustra ML, Rosmalen JG. Mood and Anxiety Disorders in Chronic Fatigue Syndrome, Fibromyalgia, and Irritable Bowel Syndrome: Results From the LifeLines Cohort Study. *Psychosom Med*. 2015;77(4):449–57.
3. Rask CU, Olsen EM, Elberling H, Christensen MF, Ornbol E, Fink P, et al. Functional somatic symptoms and associated impairment in 5–7-year-old children: the Copenhagen Child Cohort 2000. *Eur J Epidemiol*. 2009;24(10):625–34.
4. Swanson LM HJ, Feldman MD. Physician-based estimates of medically unexplained symptoms: a comparison of four case definitions. *Fam Pract*. 2010;27(5):7.
5. van der Feltz–Cornelis CM, Swinkels JA, Blankenstein AH, Hoedeman R, Keuter EJ. [The Dutch multidisciplinary guideline entitled 'Medically unexplained physical symptoms and somatoform disorder']. *Ned Tijdschr Geneesk*. 2011;155(18):A1244.
6. van der Feltz–Cornelis CM, Hoedeman R, Keuter EJ, Swinkels JA. Presentation of the Multidisciplinary Guideline Medically Unexplained Physical Symptoms (MUPS) and Somatoform Disorder in the Netherlands: disease management according to risk profiles. *J Psychosom Res*. 2012;72(2):168–9.
7. Joustra ML, Janssens KA, Bultmann U, Rosmalen JG. Functional limitations in functional somatic syndromes and well-defined medical diseases. Results from the general population cohort LifeLines. *J Psychosom Res*. 2015;79(2):94–9.
8. de Waal MW, Arnold IA, Eekhof JA, van Hemert AM. Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. *Br J Psychiatry*. 2004;184:470–6.
9. Rask MT, Rosendal M, Fenger–Gron M, Bro F, Ornbol E, Fink P. Sick leave and work disability in primary care patients with recent-onset multiple medically unexplained symptoms and persistent somatoform disorders: a 10-year follow-up of the FIP study. *Gen Hosp Psychiatry*. 2015;37(1):53–9.
10. olde Hartman TC, Borghuis MS, Lucassen PL, van de Laar FA, Speckens AE, van Weel C. Medically unexplained symptoms, somatisation disorder and hypochondriasis: course and prognosis. A systematic review. *J Psychosom Res*. 2009;66(5):363–77.
11. Lowe B, Spitzer RL, Williams JB, Mussell M, Schellberg D, Kroenke K. Depression, anxiety and somatization in primary care: syndrome overlap and functional impairment. *Gen Hosp Psychiatry*. 2008;30(3):191–9.
12. den Boeft M, van der Wouden JC, Rydell–Lexmond TR, de Wit NJ, van der Horst HE, Numans ME. Identifying patients with medically unexplained physical symptoms in electronic medical records in primary care: a validation study. *BMC family practice*. 2014;15:109.
13. Konnopka A, Kaufmann C, Konig HH, Heider D, Wild B, Szecsenyi J, et al. Association of costs with somatic symptom severity in patients with medically unexplained symptoms. *J Psychosom Res*. 2013;75(4):370–5.
14. Lantos PM, Shapiro ED, Auwaerter PG, Baker PJ, Halperin JJ, McSweeney E, et al. Unorthodox alternative therapies marketed to treat Lyme disease. *Clin Infect Dis*. 2015;60(12):1776–82.
15. Speckens AE, Van Hemert AM, Spinhoven P, Bolk JH. The diagnostic and prognostic significance of the Whitely Index, the Illness Attitude Scales and the Somatosensory Amplification Scale. *Psychol Med*. 1996;26(5):1085–90.
16. Speckens AE, Van Hemert AM, Bolk JH, Rooijmans HG, Hengeveld MW. Unexplained physical symptoms: outcome, utilization of medical care and associated factors. *Psychol Med*. 1996;26(4):745–52.
17. Kooiman CG, Bolk JH, Rooijmans HG, Trijsburg RW. Alexithymia does not predict the persistence of medically unexplained physical symptoms. *Psychosom Med*. 2004;66(2):224–32.
18. Carson AJ, Best S, Postma K, Stone J, Warlow C, Sharpe M. The outcome of neurology outpatients with medically unexplained symptoms: a prospective cohort study. *J Neurol Neurosurg Psychiatry*. 2003;74(7):897–900.
19. De Gucht V, Fischler B, Heiser W. Personality and affect as determinants of medically unexplained symptoms in primary care; A follow-up study. *J Psychosom Res*. 2004;56(3):279–85.
20. Janssens KA, Klis S, Kingma EM, Oldehinkel AJ, Rosmalen JG. Predictors for persistence of functional somatic symptoms in adolescents. *J Pediatr*. 2014;164(4):900–5 e2.

21. Steinhausen HC, Winkler Metzke C. Continuity of functional–somatic symptoms from late childhood to young adulthood in a community sample. *J Child Psychol Psychiatry*. 2007;48(5):508–13.
22. Bonvanie IJ, Rosmalen JG, van Rhede van der Kloot CM, Oldehinkel AJ, Janssens KA. Short report: Functional somatic symptoms are associated with perfectionism in adolescents. *J Psychosom Res*. 2015;79(4):328–30.
23. Scott KM, Von Korff M, Angermeyer MC, Benjet C, Bruffaerts R, de Girolamo G, et al. Association of childhood adversities and early-onset mental disorders with adult-onset chronic physical conditions. *Arch Gen Psychiatry*. 2011;68(8):838–44.
24. Leiknes KA, Finset A, Moum T, Sandanger I. Course and predictors of medically unexplained pain symptoms in the general population. *J Psychosom Res*. 2007;62(2):119–28.
25. Rask MT, Andersen RS, Bro F, Fink P, Rosendal M. Towards a clinically useful diagnosis for mild-to-moderate conditions of medically unexplained symptoms in general practice: a mixed methods study. *BMC family practice*. 2014;15:118.
26. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. *International Journal of Surgery*. 2014;12(12):1495–9.
27. de Graaf R, Ten Have M, van Dorsselaer S. The Netherlands Mental Health Survey and Incidence Study–2 (NEMESIS–2): design and methods. *Int J Methods Psychiatr Res*. 2010;19(3):125–41.
28. de Graaf R, ten Have M, van Gool C, van Dorsselaer S. Prevalence of mental disorders and trends from 1996 to 2009. Results from the Netherlands Mental Health Survey and Incidence Study–2. *Soc Psychiatry Psychiatr Epidemiol*. 2012;47(2):203–13.
29. van Eck van der Sluijs J, Ten Have M, Rijnders C, van Marwijk H, de Graaf R, van der Feltz–Cornelis C. Medically unexplained and explained physical symptoms in the general population: association with prevalent and incident mental disorders. *PloS one*. 2015;10(4):e0123274.
30. Graaf R de DSv, Tuithof M, et al. Sociodemographic and psychiatric predictors of attrition in the Netherlands Mental Health Survey and Incidence Study–2 (NEMESIS–2). *BMC Psychiatry*. Submitted.
31. Aaronson NK, Muller M, Cohen PD, Essink–Bot ML, Fekkes M, Sanderman R, et al. Translation, validation, and norming of the Dutch language version of the SF–36 Health Survey in community and chronic disease populations. *J Clin Epidemiol*. 1998;51(11):1055–68.
32. Association AP. *Diagnostic and Statistical Manual of Mental Disorders (Fifth ed.)*. Arlington, VA: American Psychiatric Publishing; 2013.
33. van Eck van der Sluijs JF, Ten Have M, Rijnders CA, van Marwijk HW, de Graaf R, van der Feltz–Cornelis CM. Mental health care use in medically unexplained and explained physical symptoms: findings from a general population study. *Neuropsychiatric disease and treatment*. 2016;12:2063–72.
34. Perruccio AV, Gandhi R, Lau JT, Syed KA, Mahomed NN, Rampersaud YR. Cross–Sectional Contrast Between Individuals With Foot/Ankle vs Knee Osteoarthritis for Obesity and Low Education on Health–Related Quality of Life. *Foot Ankle Int*. 2016;37(1):24–32.
35. Gentile S, Fusco ML. Untreated perinatal paternal depression: Effects on offspring. *Psychiatry Res*. 2017;252:325–32.
36. Gentile S. Untreated depression during pregnancy: Short– and long–term effects in offspring. A systematic review. *Neuroscience*. 2017;342:154–66.
37. Virgolino A, Heitor MJ, Carreiras J, Lopes E, Overland S, Torp S, et al. Facing unemployment: study protocol for the implementation and evaluation of a community–based intervention for psychological well–being promotion. *BMC Psychiatry*. 2017;17(1):261.
38. Infurna FJ, Luthar SS. Resilience to Major Life Stressors Is Not as Common as Thought. *Perspect Psychol Sci*. 2016;11(2):175–94.
39. Natsuaki MN, Shaw DS, Neiderhiser JM, Ganiban JM, Harold GT, Reiss D, et al. Raised by depressed parents: is it an environmental risk? *Clin Child Fam Psychol Rev*. 2014;17(4):357–67.
40. Goodman SH, Rouse MH, Connell AM, Broth MR, Hall CM, Heyward D. Maternal depression and child psychopathology: a meta–analytic review. *Clin Child Fam Psychol Rev*. 2011;14(1):1–27.
41. Sweeney S, MacBeth A. The effects of paternal depression on child and adolescent outcomes: A systematic review. *J Affect Disord*. 2016;205:44–59.
42. Stein DJ, Scott K, Haro Abad JM, Aguilar–Gaxiola S, Alonso J, Angermeyer M, et al. Early childhood adversity and later hypertension: data from the World Mental Health Survey. *Ann Clin Psychiatry*. 2010;22(1):19–28.
43. Green JG, McLaughlin KA, Berglund PA, Gruber MJ, Sampson NA, Zaslavsky AM, et al. Childhood adversities and adult psychiatric disorders in the national comorbidity survey replication I: associations with first onset of DSM–IV disorders. *Arch Gen Psychiatry*. 2010;67(2):113–23.

44. Nelson S, Baldwin N, Taylor J. Mental health problems and medically unexplained physical symptoms in adult survivors of childhood sexual abuse: an integrative literature review. *J Psychiatr Ment Health Nurs*. 2012;19(3):211–20.
45. Walker EA, Katon WJ, Hansom J, Harrop-Griffiths J, Holm L, Jones ML, et al. Psychiatric diagnoses and sexual victimization in women with chronic pelvic pain. *Psychosomatics*. 1995;36(6):531–40.
46. Guthrie E, Thompson D. Abdominal pain and functional gastrointestinal disorders. *Bmj*. 2002;325(7366):701–3.
47. Mayou R, Farmer A. ABC of psychological medicine: Functional somatic symptoms and syndromes. *Bmj*. 2002;325:265.
48. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. *Gut*. 1999;45(Suppl II):II43–II7.
49. Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? *JAMA : the journal of the American Medical Association*. 1992;268(6):760–5.
50. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. *Bmj*. 1992;305(6846):160–4.
51. Brugha T, Bebbington P, Tennant C, Hurry J. The List of Threatening Experiences: a subset of 12 life event categories with considerable long-term contextual threat. *Psychol Med*. 1985;15(1):189–94.
52. CBSvademecum. 'CBS vragenlijst chronische ziekten.'. 2005.
53. de Graaf R, Ten Have M, Tuithof M, van Dorsselaer S. First-incidence of DSM–IV mood, anxiety and substance use disorders and its determinants: Results from the Netherlands Mental Health Survey and Incidence Study–2. *J Affect Disord*. 2013.
54. Baker MM, Stabile M, Deri C. What do self-reported, objective measures of health measure? NBER Working paper series [Internet]. 2001.
55. Knight M, Stewart-Brown S, Fletcher L. Estimating health needs: the impact of a checklist of conditions and quality of life measurement on health information derived from community surveys. *J Public Health Med*. 2001;23(3):179–86.
56. National Center for Health Statistics. Evaluation of national health interview survey diagnostic reporting. Series 2: Data evaluation and methods research 1994.
57. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Sampling and methods of the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. *Acta Psychiatr Scand Suppl*. 2004(420):8–20.
58. De Graaf R, Ormel J, Ten Have M. Mental disorders and service use in The Netherlands. Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD). In: Kessler RC, Üstün TB, editors. *The WHO World Mental Health Surveys Global Perspectives on the Epidemiology of Mental Disorders*. New York: Cambridge University Press; 2008. p. 388–405.
59. Haro JM, Arbabzadeh-Bouchez S, Brugha TS, de Girolamo G, Guyer ME, Jin R, et al. Concordance of the Composite International Diagnostic Interview Version 3.0 (CIDI 3.0) with standardized clinical assessments in the WHO World Mental Health surveys. *Int J Methods Psychiatr Res*. 2006;15(4):167–80.
60. Andrews G, Peters L. The psychometric properties of the Composite International Diagnostic Interview. *Soc Psychiatry Psychiatr Epidemiol*. 1998;33(2):80–8.
61. Wittchen HU. Reliability and validity studies of the WHO–Composite International Diagnostic Interview (CIDI): a critical review. *J Psychiatr Res*. 1994;28(1):57–84.